Survivin-specific CTLs can lyse autologous malignant chronic lymphatic leukemia cells. Malignant autologous CLL cells from an HLA-A2⁺ patient with CLL and autologous immature DCs were pulsed with the cognate survivin peptide (Sv) or an irrelevant adipophilin peptide (Ad) and used as targets. Autologous nonmalignant B cells were included as controls. The antigen specificity of the CTL lines was analyzed in cold target inhibition assays using unlabeled T2 cells pulsed with the cognate survivin (Sv) peptide or the irrelevant adipophilin (Ad) at an inhibitor-to-target ratio of 20:1.